229 related articles for article (PubMed ID: 20660395)
1. Revisiting the rosiglitazone story--lessons learned.
Rosen CJ
N Engl J Med; 2010 Aug; 363(9):803-6. PubMed ID: 20660395
[No Abstract] [Full Text] [Related]
2. The rosiglitazone story--lessons from an FDA Advisory Committee meeting.
Rosen CJ
N Engl J Med; 2007 Aug; 357(9):844-6. PubMed ID: 17687124
[No Abstract] [Full Text] [Related]
3. The value equation for rosiglitazone and pioglitazone in older persons.
Zarowitz BJ
Geriatr Nurs; 2008; 29(1):9-11. PubMed ID: 18267172
[No Abstract] [Full Text] [Related]
4. Responding to an FDA warning--geographic variation in the use of rosiglitazone.
Shah ND; Montori VM; Krumholz HM; Tu K; Alexander GC; Jackevicius CA
N Engl J Med; 2010 Nov; 363(22):2081-4. PubMed ID: 21083379
[No Abstract] [Full Text] [Related]
5. Rosiglitazone and the FDA.
Krall RL
N Engl J Med; 2007 Oct; 357(17):1776-7; author reply 1777. PubMed ID: 17969232
[No Abstract] [Full Text] [Related]
6. The rosigliazone meta-analysis: lessons for the future.
Shuster JJ; Schatz DA
Diabetes Care; 2008 Mar; 31(3):e10. PubMed ID: 18308673
[No Abstract] [Full Text] [Related]
7. Lessons from the Avandia controversy: a new paradigm for the development of drugs to treat type 2 diabetes.
Misbin RI
Diabetes Care; 2007 Dec; 30(12):3141-4. PubMed ID: 18042753
[No Abstract] [Full Text] [Related]
8. The painful truth.
Nissen SE
Eur Heart J; 2010 May; 31(10):1284-5. PubMed ID: 20418344
[No Abstract] [Full Text] [Related]
9. Rosiglitazone, marketing, and medical science.
Moynihan R
BMJ; 2010 Apr; 340():c1848. PubMed ID: 20375091
[No Abstract] [Full Text] [Related]
10. Rosiglitazone and implications for pharmacovigilance.
Kazi D
BMJ; 2007 Jun; 334(7606):1233-4. PubMed ID: 17569897
[TBL] [Abstract][Full Text] [Related]
11. Panel recommends easing restrictions on rosiglitazone despite concerns about cardiovascular safety.
Mitka M
JAMA; 2013 Jul; 310(3):246-7. PubMed ID: 23860970
[No Abstract] [Full Text] [Related]
12. Diabetes drug safety update: Avandia and your heart.
Johns Hopkins Med Lett Health After 50; 2010 Jun; 22(4):1-2, 7. PubMed ID: 20572316
[No Abstract] [Full Text] [Related]
13. The truth about rosiglitazone (avandia).
Ledbetter C; Laustsen G
Nurse Pract; 2008 Jun; 33(6):10-1. PubMed ID: 18528195
[No Abstract] [Full Text] [Related]
14. The Avandia debate: an unhappy conclusion.
Bloomgarden Z; Handelsman Y
J Diabetes; 2010 Dec; 2(4):221-2. PubMed ID: 20923505
[No Abstract] [Full Text] [Related]
15. The rosiglitazone controversy: the Indian perspective.
Mohan V; Joshi SR
J Assoc Physicians India; 2007 Jul; 55():477-80. PubMed ID: 17907495
[No Abstract] [Full Text] [Related]
16. Rosiglitazone: failure of oversight or demons imagined?
Susman J
J Fam Pract; 2007 Sep; 56(9):696, 703. PubMed ID: 17764640
[No Abstract] [Full Text] [Related]
17. The rosiglitazone decision process at FDA and EMA. What should we learn?
Pouwels KB; van Grootheest K
Int J Risk Saf Med; 2012; 24(2):73-80. PubMed ID: 22751189
[TBL] [Abstract][Full Text] [Related]
18. Rosiglitazone, myocardial ischemic risk, and recent regulatory actions.
Bourg CA; Phillips BB
Ann Pharmacother; 2012 Feb; 46(2):282-9. PubMed ID: 22298606
[TBL] [Abstract][Full Text] [Related]
19. FDA on rosiglitazone. More on advisory committee decision.
Graham DJ; Gelperin K
BMJ; 2010 Sep; 341():c4868. PubMed ID: 20823021
[No Abstract] [Full Text] [Related]
20. Rosiglitazone: what went wrong?
Cohen D
BMJ; 2010 Sep; 341():c4848. PubMed ID: 20819889
[No Abstract] [Full Text] [Related]
[Next] [New Search]
